{"id":37283,"date":"2026-01-19T06:31:18","date_gmt":"2026-01-19T05:31:18","guid":{"rendered":"https:\/\/ggba.swiss\/fluosphera-raises-chf-1-15-million-to-scale-human-based-preclinical-drug-testing\/"},"modified":"2026-01-19T06:33:05","modified_gmt":"2026-01-19T05:33:05","slug":"fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/","title":{"rendered":"FluoSphera l\u00e8ve CHF 1.15 million pour des tests pr\u00e9cliniques fond\u00e9s sur des mod\u00e8les humains"},"content":{"rendered":"\n<p>La biotech genevoise <a href=\"https:\/\/www.fluosphera.com\/\">FluoSphera<\/a> a lev\u00e9 CHF 1.15 million lors d\u2019un tour de financement men\u00e9 par <a href=\"https:\/\/www.soulmatesventures.com\/\">Soulmates Ventures<\/a>, avec la participation d\u2019un business angel suisse et d\u2019<a href=\"https:\/\/indiebio.co\/\">IndieBio<\/a>. Ce nouveau financement permettra d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement de collaborations commerciales, de renforcer les activit\u00e9s de d\u00e9veloppement commercial et de poursuivre les investissements dans l\u2019automatisation et l\u2019intelligence artificielle pour l\u2019analyse d\u2019images \u00e0 grande \u00e9chelle.<\/p>\n\n\n\n<p>Spin-off de l\u2019<a href=\"https:\/\/www.unige.ch\/\">Universit\u00e9 de Gen\u00e8ve<\/a>, FluoSphera d\u00e9veloppe des syst\u00e8mes de tests pr\u00e9cliniques fond\u00e9s sur des mod\u00e8les humains visant \u00e0 am\u00e9liorer la pr\u00e9diction de la s\u00e9curit\u00e9 et de l\u2019efficacit\u00e9 des m\u00e9dicaments. L\u2019entreprise a b\u00e9n\u00e9fici\u00e9 d\u2019un soutien pr\u00e9coce de l\u2019\u00e9cosyst\u00e8me genevois de l\u2019innovation, notamment \u00e0 travers <a href=\"https:\/\/ggba.swiss\/fr\/les-start-ups-genevoises-fluosphera-kylys-aesthetics-et-consulto-recoivent-le-soutien-du-fif\/\">un financement d\u2019amor\u00e7age du Fongit Innovation Fund<\/a>. Sa technologie r\u00e9pond \u00e0 un d\u00e9fi majeur du d\u00e9veloppement pharmaceutique : plus de 90% des candidats m\u00e9dicaments \u00e9chouent lors des essais cliniques, en partie en raison des limites des mod\u00e8les pr\u00e9cliniques existants.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Une approche multiplex\u00e9e pour des tests plus repr\u00e9sentatifs de la biologie humaine<\/h4>\n\n\n\n<p>FluoSphera a mis au point une plateforme in vitro multiplex\u00e9e brevet\u00e9e capable de combiner jusqu\u2019\u00e0 six ou sept mod\u00e8les de tissus humains dans un seul puits exp\u00e9rimental. Gr\u00e2ce \u00e0 un codage fluorescent propri\u00e9taire, chaque tissu peut \u00eatre suivi ind\u00e9pendamment, permettant aux chercheurs d\u2019observer les interactions entre organes et d\u2019\u00e9valuer plus t\u00f4t l\u2019efficacit\u00e9 et les risques de toxicit\u00e9 au cours du processus de d\u00e9veloppement des m\u00e9dicaments. Cette approche vise \u00e0 d\u00e9passer les limites des cultures cellulaires 2D traditionnelles et des mod\u00e8les animaux, qui ne refl\u00e8tent souvent qu\u2019imparfaitement la biologie humaine.<\/p>\n\n\n\n<p>L\u2019entreprise collabore d\u00e9j\u00e0 avec des partenaires biotechnologiques et pharmaceutiques, notamment dans le domaine des conjugu\u00e9s anticorps-m\u00e9dicaments, et travaille avec <a href=\"https:\/\/www.revvity.com\/ch-en\">Revvity<\/a> dans le champ du criblage \u00e0 haut d\u00e9bit. Gr\u00e2ce \u00e0 ce nouveau financement, FluoSphera pr\u00e9voit d\u2019\u00e9tendre sa pr\u00e9sence aux \u00c9tats-Unis et en Europe, tout en amor\u00e7ant son d\u00e9veloppement sur le march\u00e9 asiatique, positionnant sa plateforme comme une alternative \u00e9volutive en phase avec les cadres r\u00e9glementaires favorisant les m\u00e9thodes de tests sans animaux.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La start-up genevoise FluoSphera a lev\u00e9 CHF 1.15 million afin d\u2019\u00e9tendre sa plateforme de tests pr\u00e9cliniques \u00e0 pertinence humaine, soutenant la transition vers des mod\u00e8les de d\u00e9veloppement de m\u00e9dicaments plus pr\u00e9dictifs et sans recours \u00e0 l\u2019exp\u00e9rimentation animale.<\/p>\n","protected":false},"author":6,"featured_media":37280,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1141,1171],"class_list":["post-37283","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-personalized-medicine-fr-2","tag-pharma-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FluoSphera l\u00e8ve CHF 1.15 million | GGBa<\/title>\n<meta name=\"description\" content=\"La start-up genevoise FluoSphera a lev\u00e9 CHF 1.15 million afin d\u2019\u00e9tendre sa plateforme de tests pr\u00e9cliniques \u00e0 pertinence humaine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FluoSphera l\u00e8ve CHF 1.15 million | GGBa\" \/>\n<meta property=\"og:description\" content=\"La start-up genevoise FluoSphera a lev\u00e9 CHF 1.15 million afin d\u2019\u00e9tendre sa plateforme de tests pr\u00e9cliniques \u00e0 pertinence humaine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T05:31:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T05:33:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"FluoSphera l\u00e8ve CHF 1.15 million pour des tests pr\u00e9cliniques fond\u00e9s sur des mod\u00e8les humains\",\"datePublished\":\"2026-01-19T05:31:18+00:00\",\"dateModified\":\"2026-01-19T05:33:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/\"},\"wordCount\":395,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Personalized Medicine\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/\",\"name\":\"FluoSphera l\u00e8ve CHF 1.15 million | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg\",\"datePublished\":\"2026-01-19T05:31:18+00:00\",\"dateModified\":\"2026-01-19T05:33:05+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La start-up genevoise FluoSphera a lev\u00e9 CHF 1.15 million afin d\u2019\u00e9tendre sa plateforme de tests pr\u00e9cliniques \u00e0 pertinence humaine.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"L\u2019\u00e9quipe de FluoSphera d\u00e9veloppe une plateforme in vitro multiplex\u00e9e combinant plusieurs mod\u00e8les de tissus humains afin d\u2019am\u00e9liorer la pr\u00e9diction de la s\u00e9curit\u00e9 et de l\u2019efficacit\u00e9 des m\u00e9dicaments. | \u00a9 FluoSphera\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FluoSphera l\u00e8ve CHF 1.15 million pour des tests pr\u00e9cliniques fond\u00e9s sur des mod\u00e8les humains\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FluoSphera l\u00e8ve CHF 1.15 million | GGBa","description":"La start-up genevoise FluoSphera a lev\u00e9 CHF 1.15 million afin d\u2019\u00e9tendre sa plateforme de tests pr\u00e9cliniques \u00e0 pertinence humaine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/","og_locale":"fr_FR","og_type":"article","og_title":"FluoSphera l\u00e8ve CHF 1.15 million | GGBa","og_description":"La start-up genevoise FluoSphera a lev\u00e9 CHF 1.15 million afin d\u2019\u00e9tendre sa plateforme de tests pr\u00e9cliniques \u00e0 pertinence humaine.","og_url":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-01-19T05:31:18+00:00","article_modified_time":"2026-01-19T05:33:05+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"FluoSphera l\u00e8ve CHF 1.15 million pour des tests pr\u00e9cliniques fond\u00e9s sur des mod\u00e8les humains","datePublished":"2026-01-19T05:31:18+00:00","dateModified":"2026-01-19T05:33:05+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/"},"wordCount":395,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg","keywords":["Biotech","Financing","Personalized Medicine","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/","url":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/","name":"FluoSphera l\u00e8ve CHF 1.15 million | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg","datePublished":"2026-01-19T05:31:18+00:00","dateModified":"2026-01-19T05:33:05+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La start-up genevoise FluoSphera a lev\u00e9 CHF 1.15 million afin d\u2019\u00e9tendre sa plateforme de tests pr\u00e9cliniques \u00e0 pertinence humaine.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/01\/Fluosphera-Team-1180x811-1.jpg","width":1180,"height":811,"caption":"L\u2019\u00e9quipe de FluoSphera d\u00e9veloppe une plateforme in vitro multiplex\u00e9e combinant plusieurs mod\u00e8les de tissus humains afin d\u2019am\u00e9liorer la pr\u00e9diction de la s\u00e9curit\u00e9 et de l\u2019efficacit\u00e9 des m\u00e9dicaments. | \u00a9 FluoSphera"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/fluosphera-leve-chf-1-15-million-pour-des-tests-precliniques-fondes-sur-des-modeles-humains\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"FluoSphera l\u00e8ve CHF 1.15 million pour des tests pr\u00e9cliniques fond\u00e9s sur des mod\u00e8les humains"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/37283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=37283"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/37283\/revisions"}],"predecessor-version":[{"id":37285,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/37283\/revisions\/37285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/37280"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=37283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=37283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=37283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}